Close menu




January 13th, 2022 | 18:11 CET

New research results for Covid-19: BioNTech, Cardiol, Valneva

  • Covid-19
Photo credits: pixabay.com

In the afternoon of today's trading day, the German indices extended the price losses in part after a brief recovery phase. The DAX is currently trading at 15,963 points, down around 0.41%. The psychological mark of 16,000 points was exceeded at midday in phases by more than 75 points. The MDAX last traded at 34,708 points (-0.62%), TecDAX at 3,577 points (-2.26%) and SDAX at 15,976 points with 0.66% in the red. New research results for the treatment and prevention of Covid-19 provide an exciting perspective for investors.

time to read: 1 minutes | Author: Mario Hose
ISIN: BIONTECH SE SPON. ADRS 1 | US09075V1026 , CARDIOL THERAPEUTICS | CA14161Y2006 , VALNEVA SE EO -_15 | FR0004056851

Table of contents:


    How long will vaccine shares benefit from the hype?

    The share of the Mainz-based biotech company BioNTech leads the top of the most executed orders again today. On Tradegate, the share can show 3,137 orders so far. At a price of EUR 184.05, the share is trading 4.46% down. Valneva's stock last traded at EUR 16.61, down 2.92%.

    Cannabis can prevent viral infection

    Oregon State University researchers this week presented their research report titled "Cannabinoids Block Cellular Entry of SARS-CoV-2 and the Emerging Variants." According to the report, researchers found that two cannabinoid acids, cannabigerolic acid (CBGA) and cannabidiolic acid (CBDA), found in cannabis, can bind to the spike protein of SARS-CoV-2, the virus that causes covid-19.

    Biotech company Cardiol Therapeutics is also relying on cannabidiol in its development of therapeutic options for heart problems. The company received a USD 50 million cash injection in November 2021, allowing it to move forward with clinical trials. Treatment of myocarditis may also be among the company's future therapies. In light of the fact that myocarditis is also one of the side effects of current vaccination campaigns around the globe, a successful completion of the clinical trial would be in the public interest. It is possible that investors will soon switch from vaccine shares. Cardiol's share was last quoted at EUR 1.58 and can gain 2.60%. The analysts at GBC Research recommend the share as a buy with a price target of CAD 17.49.

    More information is expected from the company at the International Investment Forum (IIF), on Feb. 17, 2022. (Free to attend: ii-forum.com).


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") currently hold or hold shares or other financial instruments of the aforementioned companies and speculate on their price developments. In this respect, they intend to sell or acquire shares or other financial instruments of the companies (hereinafter each referred to as a "Transaction"). Transactions may thereby influence the respective price of the shares or other financial instruments of the Company.
    In this respect, there is a concrete conflict of interest in the reporting on the companies.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.
    For this reason, there is also a concrete conflict of interest.
    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Mario Hose

    Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

    About the author



    Related comments:

    Commented by Mario Hose on January 14th, 2022 | 12:17 CET

    Natural active ingredient against Covid-19: BioNTech, Cardiol, Novavax, Valneva in focus

    • Covid-19

    At the end of the week, trading on the German stock exchanges has been rather slow so far. The German leading index DAX is quoted at a level of 15,922 points and thus around 0.01% up. The index of the second tier, MDAX, traded last at 34,626 points (-0.11%), TecDAX at 3,537 points (-0.67%) and SDAX at 15,904 points with 0.43% in the red. A study from the U.S. will influence the future development of vaccine manufacturers in connection with Covid-19, according to initial research.

    Read

    Commented by Mario Hose on January 12th, 2022 | 10:53 CET

    Trading stocks after EMA warning in focus: BioNTech, Johnson + Johnson, Moderna

    • Covid-19

    On Wednesday, the German indices began with a positive sign. The German benchmark index DAX is currently quoted at a level of 16,004 points and thus around 0.04% slightly up. The companies in the second tier can also hold their ground and the MDAX last traded at 34,864 points (+0.26%), TexDAX at 3,644 points and thus 0.60% lower than the previous day. SDAX also loses and last traded at 15,969 points (-0.23%).

    Read

    Commented by Fabian Lorenz on December 8th, 2021 | 14:02 CET

    Valneva, Novavax, Manganese X Energy: The new pandemic fighters?

    • Covid-19

    In the fight against the fourth wave of Corona, German industry is now also becoming active. In support of the vaccination campaign, numerous well-known corporations are changing their advertising slogans. Since November 7, more than 150 companies - including BMW, McDonald's, Edeka, Sparkassen, and Volksbanken - have been jointly promoting the corona vaccination. The campaign was developed by the Berlin advertising agency Antoni. In the future, Valneva, Novavax and Manganese X Energy want to contribute to the direct fight against the pandemic. Valneva and Novavax are in a neck-and-neck race for the first inactivated vaccine alternative to the top dogs BioNTech and Moderna. Newcomer Manganese wants to combat Corona with a new air disinfectant and has other arrows in its quiver.

    Read